Alkermes reiterates $400M-$420M Q4 proprietary net sales outlook while targeting mid-2027 alixorexton Phase III data
We haven't written up this one. Seeking Alpha News has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.